The Proliferation Inhibitory Effect of Postbiotics Prepared from  Probiotics with Antioxidant Activity against HT-29 Cells

Abstract

Prebiotics and probiotics have gained much attention in the pursuit of a healthy life. Recently, postbiotics have been spotlighted as next-generation compounds that can improve health. Postbiotics are designated into non-viable, inactivated, and ghost probiotics, and linked to several health benefits for the gut, immune system, and various other aspects of health. This study investigated the anti-proliferation effects of postbiotics against HT-29 cells, a colon cancer cell line. The postbiotics were produced by the ultrasonication method from two Lactobacillus strains (Lactobacillus sp. La1, and La2) and designated to Pobt-La1 and Pobt-La2, respectively, and non-viability was confirmed on the plate media. The anti-proliferation effect was concentration-dependent. The HT-29 cells showed viabilities of 39% and 49% when treated with 300 µL/mL of Pobt-La1 and Pobt-La2, respectively. During observation of the morphological changes of HT-29 cells when treated with IC50, a cell nucleus was not observed but cell condensation was observed. Moreover, in comparison with the control group, a reduced number of cells were observed. Based on these results, it considered that the postbiotic compounds from Lactobacillus La1 and La2 could provide crucial information in the development of anticancer research. Through further research, it would be beneficial to investigate the possibility of using these postbiotics (Pobt-La1 and -La2) as an anticancer drug.

Investigating the therapeutic potential of Bifidobacterium breve and Lactobacillus rhamnosus postbiotics through apoptosis induction in colorectal HT-29 cancer cells

“…The cells were cultured and maintained in a controlled environment at a temperature of 37°C in a 5% CO 2 atmosphere using DMEM medium (high glucose with GlutaMAX) (Bioidea, Iran). The medium was supplemented with 10% (v/v) heat-inactivated fetal bovine serum (FBS) (GIBCO® Invitrogen Corporation, CA, USA) and 100 IU/ml penicillin-streptomycin (Bioidea, Iran) to support cell growth and viability ( 17 ).…”

The Debate between the Human Microbiota and Immune System in Treating Aerodigestive and Digestive Tract Cancers: A Review

“…For instance, inosine, butyrate, or propionate could modulate the efficacy of immune checkpoint inhibitors [ 170 , 189 ]. Moreover, the use of postbiotic derived from Lactobacillus could exert antitumoral activity against HT-29 human colon cancer cells [ 190 ].…”

Probiotic-Derived Bioactive Compounds in Colorectal Cancer Treatment

“…The antiproliferative properties of CFSs against CRC cells originate from probiotics, mainly of the genus Lactobacillus [ 97 , 98 , 99 , 100 , 101 , 102 , 103 , 104 , 105 , 106 , 107 ], Bacillus [ 108 , 109 ], Enterococcus [ 110 ], Bifidobacterium [ 111 ], Leuconostoc [ 112 ], or commensal bacteria [ 113 , 114 ] and have been accredited in vitro ( Table 1 ). The CFS can promote the activation of the intrinsic apoptotic pathway as indicated by increased caspase expression [ 115 , 116 , 117 , 118 , 119 , 120 ] and other major biochemical changes, including the loss of mitochondrial membrane potential and cytochrome c release, down-regulation of the anti-apoptotic BCL2 gene, and the up-regulation of the pro-apoptotic BAK , BAD , and BAX genes [ 121 , 122 ]. Moreover, apoptosis-associated morphological alterations such as the formation of cytoplasmic blebs, chromatin condensation, and DNA fragmentation have been observed [ 123 , 124 , 125 , 126 ].…”